Nykode Therapeutics Denmark A/S
Public limited companyCVR 42038660Kongens LyngbyActive
Nykode Therapeutics Denmark A/S is a public limited company, based in Kongens Lyngby, active in business and other management consultancy activities, founded in 2021. Net profit rose 758% from 2024 to 2025, ending at DKK 1.3m. With 11 employees, the company is about 6 times larger than the industry median. Equity grew to DKK 6.9m in 2025.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- Gross profit fell 50% (2024 → 2025), to DKK 31.8m.
- Net profit rose 758% (2024 → 2025), to DKK 1.3m.
- Equity rose 24% (2024 → 2025), to DKK 6.9m.
Registrations, last 24 months
- 01/01/2025: Industry changed to Business and other management consultancy activities (702000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2021–2025 · amounts in DKK thousandEquity and net profit
| 2021 | 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | not stated | – |
| Gross profit | 10,591 | 38,639 | 52,928 | 63,553 | 31,839 | −49.9% |
| Operating profit (EBIT) | 763 | 2,613 | 3,833 | 426 | 2,244 | +426.3% |
| Profit before tax | 747 | 2,438 | 3,199 | 377 | 1,599 | +323.8% |
| Net profit | 578 | 1,895 | 2,485 | 157 | 1,347 | +758.3% |
| Total assets | 10,954 | 14,830 | 20,504 | 20,422 | 15,551 | −23.9% |
| Equity | 978 | 2,874 | 5,358 | 5,515 | 6,862 | +24.4% |
| Liabilities | 9,976 | 11,941 | 15,108 | 10,722 | 8,689 | −19% |
| Cash and cash equivalents | 9,908 | 4,885 | 7,491 | 9,248 | 6,134 | −33.7% |
| Average number of employees | 7 | 23 | 31 | 37 | 16 | −56.8% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresFewer employees
The number of employees fell 57% from 37 in 2024 to 16 in 2025.
How is this calculated?
The number of employees according to the annual report has fallen by at least 25%, and was at least 10 the year before.
Profit for five years in a row
Net result has been positive in 2021–2025.
How is this calculated?
Net result is positive in the five latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
5 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 26/06/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 23/05/2025 | The company | PDFXBRL |
| 2023 | 01/01/2023 – 31/12/2023 | 12/06/2024 | The company | PDFXBRL |
| 2022 | 01/01/2022 – 31/12/2022 | 28/06/2023 | The company | PDFXBRL |
| 2021 | 08/01/2021 – 31/12/2021 | 08/07/2022 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
2,370 companies in the databaseComparison with the other companies in business and other management consultancy activities based on the latest financial year.
Industry median: gross profit DKK 1.3m, net profit DKK 170k, equity DKK 974k, 2 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 818of 69,742 Better than 99% | No. 11,617of 69,964 Better than 83% |
| Same industry and fewer than 20 employees2,220 companies in the comparison | No. 57of 2,210 Better than 97% | No. 413of 2,219 Better than 81% |
| Companies that are between 5 and 14 years old33,688 companies in the comparison | No. 1,200of 33,588 Better than 96% | No. 4,893of 33,687 Better than 85% |
| All companies of type A/S18,025 companies in the comparison | No. 4,202of 17,786 Better than 76% | No. 10,246of 18,024 Better than 43% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Business and other management consultancy activities- Nykode Therapeutics Denmark A/SDKK 31.8m
- COWI Holding A/SDKK 7bn
- Accenture A/SDKK 1.1bn
- Nykode Therapeutics Denmark A/SDKK 1.3m
- COWI Holding A/SDKK 374m
- Accenture A/SDKK 116.1m
- Nykode Therapeutics Denmark A/SDKK 6.9m
- COWI Holding A/SDKK 2bn
- Accenture A/SDKK 642m
- Nykode Therapeutics Denmark A/S11
- COWI Holding A/S12
- Accenture A/S977
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- Nykode Therapeutics ASA100%
Management
4 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Michael Thyrring Engsig | Director | 08/01/2021 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Michael Thyrring Engsig | Board member | 08/01/2021 |
| Louise Stubbe | Chair of the board | 15/08/2022 |
| Harald Gurvin | Board member | 15/08/2022 |
- Founders
- Nykode Therapeutics ASA
Former management (4)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Lars Dencker Nielsen | Board member | 08/01/2021 | 21/04/2021 |
| Anders Tuv | Chair of the board | 08/01/2021 | 20/01/2022 |
| Katrine Hovgaard Husum | Board member | 21/04/2021 | 15/08/2022 |
| Alf Gunnar Martin Nicklasson | Chair of the board | 20/01/2022 | 15/08/2022 |
Signing rule: Selskabet tegnes af to medlemmer af bestyrelsen i forening eller af et bestyrelsesmedlem i forening med en direktør.
Address and production units
1 active production unitsGammel Lundtoftevej 1E
2800 Kongens Lyngby
Lyngby-Taarbæk Municipality · Postcode 2800
Other companies at the address (3)
- Svea Inkasso A/SActivities of collection agencies and credit bureaus
- Svea Finans A/SActivities of other credit companies
- Svea Kredit ApSActivities of other credit companies
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Nykode Therapeutics Denmark A/S | Gammel Lundtoftevej 1E, 2800 Kongens Lyngby | 12 | 1026702026 |
Purpose
Selskabets formål er at levere ledelsesmæssige, administrative og specialiserede tjenester inden for den biofarmaceutiske industri samt udøve anden virksomhed, der står i forbindelse hermed.
The purpose is quoted from the register in Danish.
Changes year by year
22 registered events20261 changeaccounts 1
- AccountsAnnual report for 2025 published
20252 changesaccounts 1 · industry 1
- AccountsAnnual report for 2024 published
- IndustryIndustry changed to Business and other management consultancy activities (702000)
20241 changeaccounts 1
- AccountsAnnual report for 2023 published
20232 changesaccounts 1 · address 1
- AccountsAnnual report for 2022 published
- AddressMoved to Gammel Lundtoftevej 1E, 2800 Kongens Lyngby
20227 changesmanagement 6 · accounts 1
- ManagementLouise Stubbe appointed chair of the board
- ManagementHarald Gurvin appointed board member
- ManagementAlf Gunnar Martin Nicklasson stepped down as chair of the board
- ManagementKatrine Hovgaard Husum stepped down as board member
- AccountsAnnual report for 2021 published
- ManagementAlf Gunnar Martin Nicklasson appointed chair of the board
- ManagementAnders Tuv stepped down as chair of the board
20219 changesname 1 · management 6 · founded 1 · ownership 1
- NameName changed from Vaccibody Denmark A/S to Nykode Therapeutics Denmark A/S
- ManagementKatrine Hovgaard Husum appointed board member
- ManagementLars Dencker Nielsen stepped down as board member
- FoundedRegistered as Vaccibody Denmark A/S
- ManagementMichael Thyrring Engsig appointed director
- ManagementAnders Tuv appointed chair of the board
- ManagementLars Dencker Nielsen appointed board member
- ManagementMichael Thyrring Engsig appointed board member
- OwnershipNykode Therapeutics ASA registered as owner (100%)
Related companies
Same industry in Lyngby-Taarbæk
- Computershare A/S27 employees
- 44 East ApS19 employees
- Weel & Sandvig Energi og Procesinnovation ApS18 employees
- Howden Financial Advisory ApS18 employees
- Talents Unlimited Denmark ApS16 employees
- PharmaLex Denmark A/S15 employees
Same people in management
- Riverty Services Denmark A/Svia Lars Dencker Nielsen
- Riverty Denmark A/Svia Lars Dencker Nielsen
- FluoGuide A/Svia Michael Thyrring Engsig
Largest in the industry
- COWI Holding A/SDKK 7bn
- Accenture A/SDKK 1.1bn
- Gts Nordic ApSDKK 968.5m
- CODAN Companies ApSDKK 877.7m
- Ferrosan Medical Devices Group A/SDKK 799.1m
- Stibo Complete Group A/SDKK 613.9m
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.